Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer

• Published in: Current cancer drug targets Vol. 14; no. 9; p. 775
• Main Authors: Subramaniam, Deepa, He, Aiwu Ruth, Hwang, Jimmy, Deeken, John, Pishvaian, Michael, Hartley, Marion L, Marshall, John L
• Format: Journal Article
• Language: English
• Published: Netherlands 2015
• Subjects: Animals; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - enzymology; Breast Neoplasms - metabolism; Drugs, Investigational - adverse effects; Drugs, Investigational - therapeutic use; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - metabolism; Female; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - enzymology; Lung Neoplasms - metabolism; Male; Molecular Targeted Therapy; Neoplasm Proteins - antagonists & inhibitors; Neoplasm Proteins - metabolism; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Receptor, Epidermal Growth Factor - metabolism; Receptor, ErbB-2 - antagonists & inhibitors; Receptor, ErbB-2 - metabolism; Receptor, ErbB-3 - antagonists & inhibitors; Receptor, ErbB-3 - metabolism; Receptor, ErbB-4 - antagonists & inhibitors; Receptor, ErbB-4 - metabolism

Overactivation of the ErbB protein family, which is comprised of 4 receptor tyrosine kinase members (ErbB1/epidermal growth factor receptor [EGFR]/HER1, ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4), can drive the development and progression of a wide variety of malignancies, including colorectal, head an...